Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter 
Professionals >> Visit The Body PROThe Body en Espanol
   
Ask the Experts About

Choosing Your MedsChoosing Your Meds
         
Rollover images to visit our other forums!
  
  • Email Email
  • Glossary Glossary


Average Rise in CD4 count
Feb 23, 2003

I was diagonosed with HIV last year and have been on a regimen of Sustiva and Combivir. My initial CD4 count was 35, second test was 54, third was 115, most recent was 150. ARe the rises in CD4 counts this small or does it vary? Thank you.

Response from Dr. Wohl

The rate at which CD4 cells return after the initiation of HIV medication is variable and depends on several known and unknown factors including what your count is before starting the medication.

Generally, the lower the CD4 cell count is before starting treatment the less robust the response. This is most true for those who had counts below 100 prior to HIV therapy.

In addition, many people with the lowest counts get an initial rise in CD4 cells but then hits a 'ceiling' usually below 200 cells/uL at which the count stays.

In your case, however, I think things look good. Your counts are almost 5 times what they were and demonstrate a continued rise. DW


Previous
Testing after 23 weeks
Next
Please Help Me its Urgent

  
  • Email Email
  • Glossary Glossary


 
Advertisement




Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement